Technology & Innovation

Oxford's OMass Therapeutics secures £10m funding from British Patient Capital

Published by
Stephen Emerson

University of Oxford spinout OMass Therapeutics has secured £10m of funding from British Patient Capital (BPC).

The biotech firm is developing small molecule therapeutics for rare diseases and immunological conditions and has secured the BPC investment as part of its Series B fundraising round which now stands at a total of £85.5 million.

BPC, a wholly owned commercial subsidiary of British Business Bank plc, the UK government’s economic development bank joins Syncona, Oxford Science Enterprises, GV, Northpond Ventures and Sanofi Ventures in the round.

READ MORE: OMass Therapeutics outlines next growth phase with new facilities and team expansion

The additional £10 million investment is from BPC’s Future Fund: Breakthrough programme, a £375million programme which co-invests with private sector investors in innovative, R&D-intensive UK companies.

The funding will be used to clinically develop OMass Therapeutics' proposition.

OMass has a current workforce of 55 and recently moved into new purpose-built facilities on ARC Oxford campus.

Catherine Lewis La Torre, CEO, British Patient Capital said: “The UK continues to demonstrate its strength in life sciences with university spinouts like OMass leading the way. Scaling next-generation technology businesses, like OMass, by providing long-term capital for investment is why we established Future Fund: Breakthrough in 2021. We are delighted to be part of this latest funding round which will allow OMass to continue to build a strong pipeline of drugs with the potential to meaningfully improve patient outcomes.”

OMass this week also announced the appointment of Jim Geraghty as chairman of its board of directors and

Boston-based Mr. Geraghty has over 35 years of strategic experience including more than 25 years as a senior executive at biotechnology companies developing and commercialising innovative therapies.

READ MORE: OMass Therapeutics raises $100 Million to progress immunology and rare diseases drug pipeline

Stephen Emerson

Stephen Emerson is the Managing Editor of The Business Magazine and is responsible for the publication's print publications and online properties including the newly launched Biz News websites in Hampshire and Dorset. Stephen has been a journalist for 20 years and has worked at local, regional and national publications and led a team which made The Scotsman website one of the fastest growing news sites in the UK with over eight million monthly users. He has a keen interest in technology, property and corporate finance and telling the stories of the people behind the successful firms in these sectors.

Recent Posts

Publisher Future plc sees in-line trading in first-half

Bath-based Future plc, the publisher of specialist online and print magazines, said trading in its…

3 days ago

IS-Instruments Ltd and Bristol university among six UKAEA contract winners

The university of Bristol was one of six organisations to receive a contract from the…

3 days ago

Oxford BioDynamics teams up with King's College in bid to boost rheumatoid arthritis prevention

Oxford BioDynamics Plc is teaming up with researchers at King's College London in a bid…

3 days ago

UK needs quarter of a million extra construction workers by 2028

More than a quarter of a million extra construction workers are needed in the UK…

3 days ago

Vistry makes good start to year, bolstered by partnership model

Kent-based housebuilder Vistry revealed it was on track to deliver more than 10% growth in…

3 days ago

Dorset start-up with green ambitions boosted by SWIG Finance loan

A Dorset-based company, which has developed ground-breaking technology to recycle plastic waste and turn it…

3 days ago